Alamar Biosciences Q3 earnings call highlights. November 3, 2026 Key points. * Third-quarter revenue rose 68% year over year to $33.5 million, led by 79% growth in consumables sales. Alamar raised its 2026 revenue outlook to $121 million-$123 million, representing 64% growth at the midpoint. * Alamar announced large-scale research collaborations with UK Biobank to profile 80,000 samples and GSK to analyze more than 60,000 samples. The company said the UK Biobank project is included in its updated guidance; it did not disclose expected revenue from either collaboration. * Gross margin improved to 61.5% from 59.7%, but higher operating expenses contributed to a $15.1 million operating loss, versus $7.9 million a year earlier. Alamar ended the quarter with $231.5 million in cash, short-term investments and restricted cash. * Five stocks we like better than Alamar Biosciences. Alamar Biosciences NASDAQ: ALMR reported third-quarter revenue growth of 68% year over year, driven by rising consumables sales, new instrument placements and its largest Technology Access Program, or TAP, services quarter to date. The precision proteomics company also raised its full-year revenue outlook and highlighted newly announced large-scale collaborations with UK Biobank and GSK. Total third-quarter revenue was $33.5 million, compared with $19.9 million in the prior-year period. Consumables revenue increased 79% to $17.8 million and accounted for 53% of total revenue, while instrument revenue rose 50% to $8.5 million. Service and other revenue, primarily TAP services, totaled $7.2 million. Chief Executive Officer Yuling Luo said the company's NULISA platform is gaining adoption among researchers and biopharmaceutical companies seeking to measure low-abundance proteins associated with disease. Alamar's platform is designed to measure hundreds of proteins from a small blood sample, with applications in neurology, inflammation, oncology and autoimmune disease research. Large-Scale study collaborations. Alamar said it was selected with Nightingale Health for UK Biobank's Vanguard study of blood-based biomarkers for neurodegenerative disease. The study is expected to profile 220 neurologically relevant proteins across 80,000 blood samples from participants who were healthy at enrollment. The study, funded by the Michael J. Fox Foundation, LifeArc and Alzheimer's Research UK, is expected to be completed by the end of 2027. Alamar said the resulting data will be integrated with UK Biobank's imaging, genetic and longitudinal health data and made available to approved researchers. Chief Financial Officer Justin McAnear said sample processing for the UK Biobank work is expected to begin in the fourth quarter and ramp during 2027. He said the anticipated fourth-quarter contribution from the project was included in the company's updated guidance, though Alamar does not break out revenue from individual projects. The company also announced a scientific partnership with GSK to profile more than 60,000 serum samples using Alamar's NULISAseq Immune 340 and Neuro 220 panels. The work will examine circulating protein signatures associated with disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions. Luo said the GSK study is scheduled to begin in the first quarter of 2027. The company did not provide a completion timeline or disclose expected revenue from the collaboration. Biopharma mix and scientific footprint. Biopharmaceutical companies represented 49% of third-quarter revenue, exceeding the 44% contribution from academic and research institutions. Distributors accounted for the remaining 7%. McAnear said this was the first quarter in which biopharma customers represented the largest share of revenue, up from 42% in the second quarter. Discover more MarketBeat All Access Stock Market News Stock Screener Tool "Biopharma customers tend to run larger, more sustained studies that drive meaningful consumables pull-through over time," McAnear said. Alamar added more than 35 publications and preprints during the quarter, bringing its cumulative total to more than 200 across neurodegenerative disease, oncology and autoimmune conditions. Luo highlighted an independent Emory University study published in Nature Communications that identified a 10-protein signature distinguishing amyotrophic lateral sclerosis, or ALS, from healthy controls with 98% balanced accuracy in a validation cohort, compared with approximately 90% for neurofilament light chain alone. The company also cited a study published in The Lancet Neurology from Washington University researchers that used Alamar's NULISAseq CNS 120 panel to measure 130 proteins across nearly 2,400 samples from patients receiving lecanemab and untreated comparison participants. Margins, expenses and outlook. Gross profit rose to $20.6 million from $11.9 million a year earlier, while gross margin expanded to 61.5% from 59.7%. McAnear said the improvement reflected lower instrument costs, higher average consumables selling prices, improved TAP services margins and a favorable product mix. Operating expenses increased to $35.8 million from $19.8 million in the prior-year quarter. Research and development expense rose 58% to $16.2 million, while selling, general and administrative expense increased 105% to $19.6 million, reflecting higher personnel, legal and accounting costs. Alamar reported an operating loss of $15.1 million, compared with a $7.9 million operating loss a year earlier. Net loss was $13.3 million, compared with $8 million in the third quarter of 2025. The company ended the quarter with $231.5 million in cash equivalents, short-term investments and restricted cash. The company raised its full-year 2026 revenue guidance to $121 million to $123 million, from a previous range of $116 million to $120 million. At the midpoint, the new outlook represents 64% annual growth. For the fourth quarter, Alamar expects sequential growth in consumables revenue but a sequential decline in TAP revenue following the unusually strong third quarter. McAnear said TAP revenue benefited from large custom assay-development projects and population studies completed during the quarter that are not expected to recur at the same level in the fourth quarter. Alamar expects fourth-quarter operating expenses to rise as it accelerates certain research and development projects initially planned for 2027. The company said those investments support its content and instrument roadmap. Clinical strategy and operating goals. Luo said Alamar remains on track to add at least 100 instruments to its installed base during 2026 and maintain average annual instrument pull-through above $400,000. The company plans to provide updated installed-base and pull-through metrics with its year-end results. The company is developing the ARGO HT/DX clinical instrument and plans to submit it for FDA marketing authorization by the end of 2027. Luo said Alamar intends to pursue a test demonstrating the platform's ultra-high sensitivity and multiplexing capabilities, while working with in vitro diagnostic and laboratory-developed-test partners on future clinical applications. Alamar also announced that President Tod White plans to retire at year-end and will remain an adviser to the company through June 2027. Luo credited White, who previously served as the company's chief financial officer and chief business officer, with helping build Alamar's finance and operations foundation and guiding it through its initial public offering. About Alamar Biosciences (NASDAQ:ALMR). Alamar Biosciences, Inc NASDAQ: ALMR is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases. Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Alamar Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alamar Biosciences wasn't on the list. While Alamar Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates. Continue following MarketBeat

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

This is an initial public offering of shares of common stock of Alamar Biosciences, Inc. We are offering 11,250,000 shares of our common stock to be sold in the offering. The initial public offering price is $17.00 per share.